Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack

Immunology

Volumn 126, Issue 2, 2009, Pages 186-200

  Markel, Gal ^a,b   Seidman, Rachel ^b   Cohen, Yifat ^a   Besser, Michal J ^b   Sinai, Tali Cohen ^b   Treves, Avraham J ^b   Orenstein, Arie ^a   Berger, Raanan ^a   Schachter, Jacob ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b Sheba Cancer Research Center   (Israel)

Author keywords

Cell surface molecules; T cells; Tolerance suppression anergy; Tumour immunity

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; GAMMA INTERFERON;

ARTICLE; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; MELANOMA; MELANOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY;

ANTIGENS, CD; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL SURVIVAL; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYTOTOXICITY, IMMUNOLOGIC; HLA-A2 ANTIGEN; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA, RECOMBINANT; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 58149302763     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.02888.x     Document Type: Article

References (50)

1. Beauchemin N, Draber P, Dveksler G et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 1999 252 : 243 9.
2. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumour marker, functions as an intercellular adhesion molecule. Cell 1989 57 : 327 34.
3. 2+-independent cell adhesion activities of biliary glycoprotein, a member of carcinoembryonic antigen family, expressed on CHO cell surface. Biochem Biophys Res Commun 1992 186 : 881 7.
4. Watt SM, Teixeira AM, Zhou GQ et al. Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site. Blood 2001 98 : 1469 79.
5. Markel G, Gruda R, Achdout H et al. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J Immunol 2004 173 : 3732 9.
6. Beauchemin N, Kunath T, Robitaille J, Chow B, Turbide C, Daniels E, Veillette A. Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells. Oncogene 1997 14 : 783 90.
7. Busch C, Hanssen TA, Wagener C, OBrink B. Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. Hum Pathol 2002 33 : 290 8.
8. Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Inhibition of prostate tumour angiogenesis by the tumour suppressor CEACAM1. J Biol Chem 2002 277 : 35696 702.
9. Thies A, Moll I, Berger J et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002 20 : 2530 6.
10. Poy MN, Yang Y, Rezaei K et al. CEACAM1 regulates insulin clearance in liver. Nat Genet 2002 30 : 270 6.
11. Kammerer R, Hahn S, Singer BB, Luo JS, von Kleist S. Biliary glycoprotein (CD66a), a cell adhesion molecule of the immunoglobulin superfamily, on human lymphocytes: structure, expression and involvement in T cell activation. Eur J Immunol 1998 28 : 3664 74.
12. Moller MJ, Kammerer R, Grunert F, von Kleist S. Biliary glycoprotein (BGP) expression on T cells and on a natural-killer-cell sub-population. Int J Cancer 1996 65 : 740 5.
13. Morales VM, Christ A, Watt SM et al. Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a). J Immunol 1999 163 : 1363 70.
14. + T lymphocytes. Nat Immunol 2002 3 : 229 36.
15. Nagaishi T, Pao L, Lin SH et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity 2006 25 : 769 81.
16. Markel G, Lieberman N, Katz G et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 2002 168 : 2803 10.
17. Markel G, Wolf D, Hanna J et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 2002 110 : 943 53.
18. Markel G, Mussaffi H, Ling KL et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 2004 103 : 1770 8.
19. Stern N, Markel G, Arnon TI, Gruda R, Wong H, Gray-Owen SD, Mandelboim O. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol 2005 174 : 6692 701.
20. Laack E, Nikbakht H, Peters A et al. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol 2002 20 : 4279 84.
21. Sienel W, Dango S, Woelfle U et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res 2003 9 : 2260 6.
22. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005 23 : 2346 57.
23. Markel G, Seidman R, Stern N et al. Inhibition of human tumour infiltrating lymphocytes (TIL) effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 (CEACAM1) interactions. J Immunol 2006 177 : 6062 71.
24. Dudley ME, Wunderlich J, Shelton TE, Even J, Rosenberg SA. Generation of tumour-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003 26 : 332 42.
25. Kammerer R, Riesenberg R, Weiler C, Lohrmann J, Schleypen J, Zimmermann W. The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma. J Pathol 2004 204 : 258 67.
26. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996 14 : 369 96.
27. Takahashi H, Okai Y, Paxton RJ, Hefta LJ, Shively JE. Differential regulation of carcinoembryonic antigen and biliary glycoprotein by gamma-interferon. Cancer Res 1993 53 : 1612 9.
28. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001 13 : 458 64.
29. Porgador A, Mandelboim O, Restifo NP, Strominger JL. Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci U S A 1997 94 : 13140 5.
30. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon. Annu Rev Immunol 1997 15 : 749 95.
31. Ikeda H, Old LJ, Schreiber RD. The roles of IFNin protection against tumour development and cancer immunoediting. Cytokine Growth Factor Rev 2002 13 : 95 109.
32. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumour evasion of immune surveillance. Cancer Cell 2005 8 : 369 80.
33. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002 419 : 734 8.
34. Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumour regression and tumour escape. J Immunol 2006 176 : 3374 82.
35. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. Beta2-microglobulin mutations, HLA class I antigen loss, and tumour progression in melanoma. J Clin Invest 1998 101 : 2720 9.
36. So T, Takenoyama M, Mizukami M et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005 65 : 5945 52.
37. Bai XF, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanism for tumour evasion of destruction by cytolytic T lymphocytes. J Clin Invest 2003 111 : 1487 96.
38. Nowbakht P, Ionescu MC, Rohner A et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005 105 : 3615 22.
39. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996 184 : 1075 82.
40. Huber V, Fais S, Iero M et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005 128 : 1796 804.
41. Yamshchikov GV, Mullins DW, Chang CC et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 2005 174 : 6863 71.
42. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 1993 11 : 571 611.
43. Egwuagu CE, Li W, Yu CR, Che Mei Lin M, Chan CC, Nakamura T, Chepelinsky AB. Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene 2006 25 : 3670 9.
44. Qin Z, Blankenstein T. CD4+ T cell-mediated tumour rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells. Immunity 2000 12 : 677 86.
45. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989 7 : 145 73.
46. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Controversies on the prognostic significance of tumour infiltrating leukocytes in solid human tumours. Anticancer Res 2000 20 : 1759 68.
47. + T cells responding to infection. J Immunol 2005 174 : 6791 802.
48. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002 20 : 217 51.
49. Yasui H, Takai K, Yoshida R, Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci USA 1986 83 : 6622 6.
50. Leung N, Turbide C, Olson M, Marcus V, Jothy S, Beauchemin N. Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis. Oncogene 2006 25 : 5527 36.